Madrigal PharmaceuticalsMIL:1MDGL 8 PB Ratio is 20.39 as of Jun. 26, 2026, which is 105% above its 10-year median of 9.96. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Madrigal Pharmaceuticals ranks worse than 94.16% on this metric.
Madrigal Pharmaceuticals Inc stock PB Ratio (=21.78) is close to 2-year high of 23.19.
The historical rank and industry rank for Madrigal Pharmaceuticals's PB Ratio or its related term are showing as below:
MIL:1MDGL'
s PB Ratio Range Over the Past 10 Years
Min: 5.38 Med: 9.96 Max: 23.19
Current: 21.78
During the past 13 years, Madrigal Pharmaceuticals's highest PB Ratio was 23.19. The lowest was 5.38. And the median was 9.96.
MIL:1MDGL's PB Ratio is ranked worse than 94.16% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs MIL:1MDGL: 21.78
During the past 12 months, Madrigal Pharmaceuticals's average Book Value Per Share Growth Rate was -26.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 34.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Madrigal Pharmaceuticals was 250.30% per year. The lowest was -46.70% per year. And the median was 6.50% per year.
Back to Basics: PB Ratio
Madrigal Pharmaceuticals (MIL:1MDGL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1MDGL vs BMRN, ARWR, AXSM: PB Ratio Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Madrigal Pharmaceuticals (MIL:1MDGL) has a PB Ratio of 20.39 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Madrigal Pharmaceuticals and its competitors. This is 105% above median its historical median of 9.96. Over the past decade, Madrigal Pharmaceuticals' PB Ratio has ranged from 5.38 to 23.19. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #1160 out of 1232 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Madrigal Pharmaceuticals' PB Ratio too high?
Madrigal Pharmaceuticals' current PB Ratio of 20.39 is 105% above median its 10-year median of 9.96. Over the past 10 years, this metric has ranged from a low of 5.38 to a high of 23.19. The Biotechnology industry median PB Ratio is 2.80. Madrigal Pharmaceuticals' value of 20.39 is 628.2% above this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #1160 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' PB Ratio compare to BMRN and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #1160 out of 1232 companies for PB Ratio. This places Madrigal Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.80. Madrigal Pharmaceuticals' value of 20.39 is 628.2% above this benchmark. Historically, Madrigal Pharmaceuticals' own PB Ratio has ranged from 5.38 to 23.19 over the past decade. While the company's 10-year median is 9.96 vs. the industry median of 2.80, Madrigal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current PB Ratio of 20.39 is 628.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Madrigal Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current PB Ratio is 20.39, which is 105% above median its own 10-year median of 9.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current PB Ratio of 20.39. The current PB Ratio is 20.39, which is 105% above median its 10-year median of 9.96 and 628.2% above the Biotechnology industry median of 2.80. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current PB Ratio is 20.39 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score
Get the complete analysis for MIL:1MDGL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1MDGL has been successfully added to your 
